Trajectory Analysis for Sport and Video Surveillance

In video surveillance and sports analysis applications, object trajectories offer the possibility of extracting rich information on the underlying behavior of the moving targets. To this end we introduce an extension of Point Distribution Models (PDM) to analyze the object motion in their spatial, temporal and spatiotemporal dimensions. These trajectory models represent object paths as an average trajectory and a set of deformation modes, in the spatial, temporal and spatiotemporal domains. Thus any given motion can be expressed in terms of its modes, which in turn can be ascribed to a particular behavior. The proposed analysis tool has been tested on motion data extracted from a vision system that was tracking radio-guided cars running inside a circuit. This affords an easier interpretation of results, because the shortest lap provides a reference behavior. Besides showing an actual analysis we discuss how to normalize trajectories to have a meaningful analysis

Labolmage: a workstation environment for research in image processing and analysis

Numerous images are produced daily in biomedical research. In order to extract relevant and useful results, various processing and analysis steps are mandatory. The present paper describes a new, powerful and user-friendly image analysis system: Labolmage. In addition to standard image processing modules, Labolmage also contains various specialized tools. These multiple processing modules and tools are first introduced. A one-dimensional gel analysis method is then described. The new concept of ‘normalized virtual one-dimensional gel' is introduced, making comparisons between gels particularly easy. This normalized gel is obtained by compensating for the bending of the lanes automatically; no information loss is incurred in the process. Finally, the model of interaction in a multi-window environment is discussed. Labolmage is designed to run in two ways: interactively, using menus and panels; and in batch mode by means of user-defined macros. Examples are given to illustrate the potentialities of the softwar

Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.

BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS: Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 were included in the study. Clinical and biological assessment of toxicity was performed at each visit. Tumour response was assessed every 3 cycles of treatment. A database was created to collect clinical, pathological and treatment data. RESULTS: Two hundred and fifty-eight patients were included in the study. Median age was 59 years old. Tumours were Hormone Receptor (HR)-positive (73.3 %) HER2-positive (10.2 %), and triple negative (TN, 22.5 %). 86.4 % of the patients presented with visceral metastases, mainly in the liver (67.4 %). Median previous metastatic chemotherapies number was 4 [1-9]. Previous treatments included anthracyclines and/or taxanes (100 %) and capecitabine (90.7 %). Median number of EM cycles was 5 [1-19]. The relative dose intensity was 0.917. At the time of analysis (median follow-up of 13.9 months), 42.3 % of the patients were still alive. The objective response rate was 25.2 % (95 %CI: 20-31) with a 36.1 % clinical benefit rate (CBR). Median time to progression (TTP) and overall survival were 3.97 (95 %CI: 3.25-4.3) and 11.2 (95 %CI: 9.3-12.1) months, respectively. One- and 2-year survival rates were 45.5 and 8.5 %, respectively. In multivariate analysis, HER2 positivity (HR = 0.29), the presence of lung metastases (HR = 2.49) and primary taxanes resistance (HR = 2.36) were the only three independent CBR predictive factors, while HR positivity (HR = 0.67), the presence of lung metastases (HR = 1.52) and primary taxanes resistance (HR = 1.50) were the only three TTP independent prognostic factors. Treatment was globally well tolerated. Most common grade 3-4 toxicities were neutropenia (20.9 %), peripheral neuropathy (3.9 %), anaemia (1.6 %), liver dysfunction (0.8 %) and thrombocytopenia (0.4 %). Thirteen patients (5 %) developed febrile neutropenia. CONCLUSION: EM is an effective new option in heavily pretreated MBC, with a favourable efficacy/safety ratio in a clinical practice setting. Our results comfort the use of this new molecule and pledge for the evaluation of EM-trastuzumab combination in this setting. Tumour biology, primary taxanes sensitivity and metastatic sites could represent useful predictive and prognostic factors